Published in Respir Res on April 20, 2016
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Lung cancer. N Engl J Med (2008) 13.49
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Chronic obstructive pulmonary disease in non-smokers. Lancet (2009) 6.41
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
Woodsmoke health effects: a review. Inhal Toxicol (2007) 6.19
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics (2012) 4.48
A framework for oligonucleotide microarray preprocessing. Bioinformatics (2010) 3.97
Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev (2008) 3.67
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med (2007) 3.58
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med (2007) 3.09
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer (2006) 2.90
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res (2004) 2.35
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res (2007) 2.10
[National consensus of diagnosis and treatment of non-small cell lung cancer]. Rev Invest Clin (2013) 2.04
Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol (2011) 1.99
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 1.97
Respiratory symptoms in Indian women using domestic cooking fuels. Chest (1991) 1.91
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
The toxicology of inhaled woodsmoke. J Toxicol Environ Health B Crit Rev (2002) 1.73
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (2007) 1.65
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol (2003) 1.57
Lung cancer pathogenesis associated with wood smoke exposure. Chest (2005) 1.47
MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 1.25
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets (2010) 1.25
Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke particulate matter in human A549 and THP-1 cell lines. Chem Res Toxicol (2011) 1.24
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci (2011) 1.21
Matrix metalloproteinases activity in COPD associated with wood smoke. Chest (2004) 1.17
Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med (2010) 1.10
Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol (2012) 1.04
Expression of gec1/GABARAPL1 versus GABARAP mRNAs in human: predominance of gec1/GABARAPL1 in the central nervous system. Brain Res Mol Brain Res (2003) 1.03
Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer (2011) 1.02
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) (2003) 0.99
Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol (2011) 0.98
Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol (2015) 0.98
Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis (2004) 0.95
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer (2014) 0.95
Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer. Cancer Res (2005) 0.92
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol (2015) 0.90
GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol (2004) 0.89
Cigarette smoke condensate induces differential expression and promoter methylation profiles of critical genes involved in lung cancer in NL-20 lung cells in vitro: short-term and chronic exposure. Int J Toxicol (2012) 0.89
Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". Lung Cancer (2015) 0.86
High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br J Cancer (2010) 0.86
Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers (2013) 0.81
Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo. Sci Rep (2015) 0.81
Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J Thorac Oncol (2008) 0.79
Integrating smoking cessation into lung cancer screening programs. Clin Imaging (2015) 0.79
Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res (2015) 0.78
Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol (2012) 0.78